Neuronetics Prices Stock Sale At $1.60 To Fund Debt Repayment And Operations
The company expects about $27.7 million after expenses, with lender relief tied to a prepayment of at least $15 million.
Neuronetics, which makes brain-stimulation treatments and operates mental-health clinics, priced a stock sale Tuesday at $1.60 per share, seeking approximately $30 million before expenses. The company plans to put part of the money toward debt repayment, according to its SEC filing Thursday.
A $15 Million Gate To Relief
Neuronetics' lender, Perceptive Credit Holdings IV, agreed last Thursday to ease certain revenue requirements if the company meets conditions that include a minimum $15 million prepayment. Neuronetics must also pay accrued interest, an early repayment fee, an amendment fee and lender costs.
The company expects that meeting those conditions and securing the lower revenue requirements would resolve the going-concern risk cited in recent quarterly reports—the risk to its ability to keep operating.
The Perceptive facility had $65 million outstanding as of September 30, 2026, when its interest rate was 11.5%. It matures on July 25, 2029. Neuronetics borrowed $10 million under a second tranche on August 1, 2025, and prepaid $5 million of that borrowing in March 2026.
New Shares, Cash After Expenses
The base offering comprises 18,750,000 newly issued shares. Neuronetics estimates it will receive approximately $27.7 million after underwriting charges and offering expenses, or $31.9 million if the additional-share option is fully exercised.
Underwriters have 30 days to buy up to 2,812,500 additional shares. Issuing the shares would spread existing holders' ownership across a larger share count.
William Blair, the lead underwriter, is managing the sale alongside BTIG and Canaccord Genuity, the additional bookrunners. Neuronetics expects the offering to close Thursday.
Beyond debt repayment, the company intends to use proceeds for operations, including marketing, research, inventory, working capital and capital spending. Potential purchases or establishment of healthcare practices are also among its planned uses.
NeuroStar And The Greenbrook Clinics
Neuronetics sells its NeuroStar Advanced Therapy System and recurring treatment sessions, mainly to U.S. psychiatrists. The office-based system uses transcranial magnetic stimulation, a noninvasive technique that stimulates brain areas associated with mood.
NeuroStar has FDA clearance for major depressive disorder, as well as adult obsessive-compulsive disorder and anxiety symptoms in adults with depression. Neuronetics also runs 93 Greenbrook treatment centers. Clinic revenue and treatment sessions generate most of its sales; revenue totaled $149.2 million in 2025.
The lender amendment will terminate automatically unless its conditions are met or waived by November 30.
Sources
- 8-K Filing — Neuronetics, Inc. (STIM) — SEC EDGAR
- Exhibit d428716dex991.htm — Neuronetics, Inc. 8-K exhibit — SEC EDGAR
- Exhibit d428716dex992.htm — Neuronetics, Inc. 8-K exhibit — SEC EDGAR
- Neuronetics Announces Pricing of $30 Million Underwritten Public Offering of Common Stock — Yahoo Finance
- Neuronetics Announces Pricing of $30 Million Underwritten — globenewswire.com
- Neuronetics Announces Proposed Public Offering of Common — globenewswire.com